^
    Back
    Association details:
    Biomarker:IGF1R underexpression
    Cancer:Ewing Sarcoma
    Drug Class:mTOR inhibitor +
    IGF-1R inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer
    Title:

    IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

    Published date:
    07/02/2020
    Excerpt:
    We performed a meta-analysis of five phase-1b/2 ES-oriented trials that evaluated the anticancer activity of IGF-1R antibodies +/− mTOR inhibitors (mTORi)....Low pIGF-1R in the pretreatment specimens was associated with treatment response.
    DOI:
    10.3390/cancers12071768